Bionano Genomics(BNGO) - 2025 Q4 - Annual Results

Financial Results - Bionano Genomics, Inc. reported preliminary financial results for Q4 and fiscal year ended December 31, 2025[4] - The report does not include specific financial figures or performance metrics in the provided content[5] - The financial results are not deemed "filed" under the Securities Exchange Act, limiting liability under that section[5] Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BNGO[2] - The company is classified as an emerging growth company under the Securities Act[3] - R. Erik Holmlin, Ph.D., serves as the President and CEO, acting as the principal executive and financial officer[10] Report Details - The press release detailing these results was issued on January 12, 2026[6] - The report includes an Inline XBRL exhibit for the cover page of the Current Report[6] - The report does not provide details on user data, future outlook, or new product developments[5] - No information on market expansion or mergers and acquisitions is included in the content[5]